METHOD FOR PRODUCING 7H-PYRROLO [2, 3-d] PYRIMIDIN-4-AMINE DERIVATIVE
By deprotecting the protective group of the terminal acetylene under alkaline conditions and using silicon-linked protective group, the problems of excessive impurities and low yield in compound (1) in mass production are solved, and high-efficiency and low impurities API manufacturing is achieved.
Patent Information
- Application Number
- CN202380035192.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2023-04-21
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, the synthetic path of compound (1) has insufficient in mass production, especially the problems of excessive impurities and low yield, which is difficult to meet the large-scale manufacturing needs of APIs.
By deprotecting the protective group of the terminal acetylene under alkaline conditions, using silicon-linked protective groups such as TES or TIPS to avoid column chromatography purification, the efficient synthesis of compound (1) is achieved.
The production of the compound (1) with less impurity mixing and high yield is achieved, and the use of fluorine-containing reagents and explosive reagents is avoided, and the purity and production efficiency of the product are improved.
Smart Images

Figure CN119053605A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for producing a 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivative and a 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivative that can be produced in large quantities. Background Art
[0002] In the industrial manufacturing of active pharmaceutical ingredients (hereinafter referred to as API), the process of manufacturing API from raw materials requires a small number of steps and a high yield. In addition, the manufacture of API requires mass production, so operations that are not suitable for mass production are not desired. In addition, the quality of API manufactured by such a process must meet the standards specified by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (hereinafter referred to as ICH), etc. The objects of the standards can include impurities contained in the API, residual solvents, and residual metals.
[0003] Patent document 1 discloses N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide (hereinafter also referred to as compound (1)) as a compound having an EGFR inhibitory effect. In addition, as an example of a production method thereof, the following route is described: a compound represented by formula (XXII) and a compound represented by formula (XXIII) are reacted by Sonogashira coupling to introduce an R1-C≡C- group (R1 is a hydrogen atom or a C1-C3 alkyl group optionally having a substituent) to obtain a compound represented by formula (XXIV), then, by deprotecting the amine, the compound is converted to formula (XXV), and finally, by performing an acylation reaction, a compound represented by formula (XXVI) is synthesized.
[0004]
[0005] Prior art literature
[0006] Patent Literature
[0007] Patent Document 1: International Publication No. WO2020 / 166680 Summary of the invention
[0008] Problems to be solved by the invention
[0009] However, there is still room for further research on methods suitable for mass production as a synthetic route for compounds. Under such circumstances, a method for producing a compound (1) suitable for mass synthesis as an API or a compound represented by formula (I) described later is sought. In particular, a method for producing a compound (1) or a compound represented by formula (I) described later is sought that has one or more of the following characteristics suitable for mass synthesis as an API: less impurities and high yield.
[0010] Methods for solving problems
[0011] The inventors of the present invention have conducted intensive studies and have completed a method for producing a compound represented by formula (I) having one or more characteristics suitable for large-scale synthesis by deprotecting the terminal acetylene protecting group under basic conditions.
[0012] That is, the present invention provides, for example, the following [1] to
[14] .
[0013] [1] A method for producing a compound represented by formula (I) or a salt thereof, comprising:
[0014] The step of deprotecting the protecting group represented by R1 of formula (II) under alkaline conditions to form a compound represented by formula (I) or a salt thereof,
[0015]
[0016] (In the above formula (I) and formula (II),
[0017] R1 represents a protecting group,
[0018] R2 represents an amino group (amine) optionally having a protecting group, a halogen atom or a leaving group,
[0019] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
[0020] [2] The production method according to [1], wherein in the above formula (I) and formula (II), R1 represents a silicon-bonded protective group, R2 represents an amino group (amine), and R3 represents a pyrazine group optionally having a methyl group.
[0021] [3] The production method according to [1] or [2], wherein the compound represented by the above formula (I) is N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
[0022] [4] A method for producing a compound represented by formula (I) or a salt thereof, comprising:
[0023] (1) a step of deriving a compound represented by formula (III-2) by connecting the compound represented by formula (III-1) with the compound represented by formula (VIII); or a step of producing a compound represented by formula (V-1) by connecting the compound represented by formula (III-1) with the compound represented by formula (IV);
[0024]
[0025]
[0026] (2) a step of deriving a compound represented by formula (II) by connecting the compound represented by formula (III-2) with the compound represented by formula (IV), or by connecting the compound represented by formula (V-1) with the compound represented by formula (VIII); and
[0027]
[0028] (3) a step of deprotecting the protecting group represented by R1 of formula (II) under alkaline conditions to form a compound represented by formula (I) or a salt thereof,
[0029]
[0030] (In the above formulae (I), (II), (III-1), (III-2), (IV), (V-1) and (VIII),
[0031] R1 represents a protecting group,
[0032] R2 represents an amino group (amine) optionally having a protecting group, a halogen atom or a leaving group,
[0033] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent,
[0034] R5 and R5' independently represent a hydrogen atom or an amino (amine) protecting group, or NR5R5' represents phthalimide or nitro,
[0035] X represents a halogen atom or a leaving group).
[0036] [5] The manufacturing method according to [4], wherein
[0037] In the above formulae (I), (II), (III-1), (III-2), (IV) and (V-1),
[0038] R1 represents a silicon-linked protective group,
[0039] R2 represents an amino group (amine),
[0040] R3 represents a pyrazinyl group optionally having a methyl group,
[0041] R5 represents a hydrogen atom or Boc, and R5' represents a hydrogen atom.
[0042] [6] The production method according to [4] or [5], wherein
[0043] The compound represented by the above formula (I) is N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
[0044] [7] The manufacturing method according to [4], wherein
[0045] a step of reacting the compound represented by formula (VI) with the compound represented by formula (VII) to obtain a compound represented by formula (IX), and
[0046] A step of obtaining a compound represented by formula (III-1) from a compound represented by formula (IX),
[0047]
[0048] (wherein L represents a halogen atom or a leaving group)
[0049]
[0050] (In formula (VI) and formula (IX),
[0051] R4 represents NR5R5',
[0052] R5 and R5' independently represent a hydrogen atom or an amino protecting group, or NR5R5' represents phthalimide or a nitro group,
[0053] L represents a halogen atom or a leaving group).
[0054] [8] The manufacturing method according to [7], wherein
[0055] In the formulae (VI), (VII) and (IX),
[0056] R4 represents NR5R5',
[0057] R5 represents Boc, R5' represents a hydrogen atom,
[0058] L represents a chlorine atom.
[0059] [9] The production method according to any one of [4] to [8], wherein
[0060] Purification by column chromatography was not included.
[0061]
[10] The production method according to any one of [1] to [9], wherein
[0062] In the compound represented by the above formula (I) and its salt obtained by the above method, the content of the compound represented by the formula (I-1) is 0.2% or less,
[0063]
[0064] (Where,
[0065] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
[0066]
[11] A composition obtained by the method according to any one of [1] to
[10] , comprising a compound represented by formula (I) or a salt thereof.
[0067]
[12] A compound represented by formula (II) or a salt thereof,
[0068]
[0069] (Where,
[0070] R1 represents a protecting group,
[0071] R2 represents an amino group optionally having a protecting group, a halogen atom or a leaving group,
[0072] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
[0073]
[13] The compound or salt thereof according to
[12] , wherein
[0074] In the above formula (II), R1 represents a silicon-bonded protective group, R2 represents an amino group, and R3 represents a pyrazine group optionally having a methyl group.
[0075]
[14] The compound or salt thereof according to
[12] or
[13] , wherein
[0076] The compound represented by the above formula (II) is N-(4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
[0077] Effects of the Invention
[0078] According to a manufacturing method of one embodiment of the present invention, it is possible to provide a method for manufacturing a compound (1) or a compound represented by formula (I) described later, which has one or more of the following characteristics, which are suitable for large-scale synthesis of API, including less impurities and high yield. According to a preferred manufacturing method of the present invention, it is possible to provide a manufacturing method that also has one or more characteristics of not using a fluorine-containing reagent, not using an explosive reagent, and being able to avoid purification by column chromatography.
[0079] According to one embodiment of the present invention, a method for producing a compound represented by formula (I) or a salt thereof by deprotecting the protecting group represented by R1 of the compound represented by formula (II) under alkaline conditions without purification by column chromatography is provided. The method described in Patent Document 1 requires purification by silica gel column chromatography.
[0080]
[0081] (wherein, R1 represents a protecting group, R2 represents an amino group, a halogen atom or a leaving group which may have a protecting group, and R3 represents a 5-10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent)
[0082]
[0083] (Wherein, R2 and R3 are the same as above.)
[0084] The steps for converting formula (II) to formula (I) are described below.
[0085] In this specification, R1 represents a protecting group, which is a substituent for protecting the hydrogen atom of the terminal acetylene in formula (I). Terminal acetylene refers to an acetylene in which one of the two hydrogen atoms in acetylene is substituted, and refers to -C≡CH (also referred to as acetylene group) in formula (I). In one embodiment of the present invention, R1 can be any protecting group as long as it can be deprotected under alkaline conditions. As such a protecting group in R1, a protecting group (carbon-linked protecting group) in which the hydrogen atom of the terminal acetylene is substituted with a carbon atom, a protecting group (silicon-linked protecting group) substituted with a silicon atom, a protecting group (phosphorus-linked protecting group) substituted with a phosphorus atom, etc. can be listed.
[0086] In the present specification, examples of the carbon-bonded protecting group include tert-butyl, cycloalkyl, 2-hydroxypropane-2-yl and dimethylaminomethyl groups, and 2-hydroxypropane-2-yl is preferred.
[0087] In the present specification, examples of silicon-linked protecting groups include TMS (trimethylsilyl), TES (triethylsilyl), TBS (tert-butyldimethylsilyl), TIPS (triisopropylsilyl), and TBDPS (tert-butyldiphenylsilyl), etc. TES or TIPS is preferred, and TES is more preferred.
[0088] In the present specification, examples of the phosphorus-linked protecting group include -PPh2 (diphenylphosphine) and -P(O)Ph2, and -P(O)Ph2 (Ph represents a phenyl group) is preferred.
[0089] In one embodiment of the present invention, R1 is a protecting group that can be deprotected under alkaline conditions, and can convert analogs such as the compound represented by formula (I-1) that may be generated as a by-product in the reaction process into the target compound at the same time as the deprotection. This conversion can reduce the mixing of impurities and provide a high yield, thereby achieving high purity as a raw material for pharmaceuticals.
[0090]
[0091] (Wherein, R3 is the same as above.)
[0092] In one embodiment of the present invention, R1 is preferably a protecting group selected from a carbon-linked protecting group, a silicon-linked protecting group and a phosphorus-linked protecting group, more preferably a silicon-linked protecting group, further preferably TMS (trimethylsilyl), TES (triethylsilyl), TBS (tert-butyldimethylsilyl), TIPS (triisopropylsilyl) and TBDPS (tert-butyldiphenylsilyl), particularly preferably TES (triethylsilyl).
[0093] In the compound used in the production method according to one embodiment of the present invention, R2 is an amino group which may have a protecting group, a halogen atom or a leaving group.
[0094] The protecting group of the "amino group optionally having a protecting group" in R2 is not particularly limited, and examples thereof include carbamate protecting groups such as tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz or Z), 9-fluorenylmethoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), 2,2,2-triethoxycarbonyl (Troc), o-nitrobenzenesulfonyl (o-Ns, Ns, Nitrobenzenesulfonyl or o-Nitrobenzenesulfonyl), p-nitrobenzenesulfonyl (p-Ns or p-Nitrobenzenesulfonyl), and the like. The protecting groups of R2 are sulfonamide protecting groups such as zenesulfonyl, 2,4-dinitrobenzenesulfonyl (DNs), SES (2-trimethylsilylethanesulfonyl), and phthalamide protecting groups, preferably amino, amino having a carbamate protecting group, and phthalimide, more preferably amino, and amino having 1 or 2 protecting groups selected from Boc, Cbz, Fmoc, Alloc and Troc, more preferably amino, and amino having 1 or 2 protecting groups selected from Boc, Cbz, and Fmoc, and particularly preferably amino.
[0095] Examples of the halogen atom in R2 include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and a chlorine atom is preferred.
[0096] As the leaving group in R2, -OSO2C n F n+2 (n represents an integer of 1 to 4), -SO2C n F n+2 , methanesulfonate (-OMs; Ms represents methanesulfonyl), methanesulfonyl, toluenesulfonate (-OTs; Ts represents p-toluenesulfonyl), p-toluenesulfonyl, nitrobenzenesulfonate (-ONs or -Op-Ns), p-nitrobenzenesulfonyl, -OSO2Ph (Ph represents phenyl), -SO2Ph, phenoxy (-OPh), etc., preferably methanesulfonyl. Alternatively, the leaving group may be -OSO2C n F 2n+1 (n represents an integer of 1 to 4), -SO2C n F 2n+1 , methanesulfonate (-OMs; Ms represents methanesulfonyl), methanesulfonyl, toluenesulfonate (-OTs; Ts represents p-toluenesulfonyl), p-toluenesulfonyl, nitrobenzenesulfonate (-ONs or -Op-Ns), p-nitrobenzenesulfonyl, -OSO2Ph (Ph represents phenyl), -SO2Ph, phenoxy (-OPh), etc.
[0097] In the compound used in the production method according to one embodiment of the present invention, R2 is an amino group, a halogen atom or a leaving group which may have a protecting group, or R2 is phthalimide. Preferably, it is an amino group, an amino group having one or two protecting groups selected from Boc, Cbz, Fmoc, Alloc, Troc, and Ns, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, -OSO2C n F n+2 (n represents an integer of 1 to 4), -SO2C n F n+2 , methanesulfonate, methanesulfonyl, toluenesulfonate, p-toluenesulfonyl, nitrobenzenesulfonate, p-nitrobenzenesulfonyl, -OSO2Ph, -SO2Ph, and phenoxy, or R2 is phthalimide, more preferably amino, Boc, Cbz, Fmoc, chlorine atom, and methanesulfonyl, more preferably amino, chlorine atom, and methanesulfonyl, particularly preferably amino. Alternatively, R2 is amino, amino having one or two protecting groups selected from Boc, Cbz, Fmoc, Alloc, Troc and Ns, fluorine atom, chlorine atom, bromine atom, iodine atom, -OSO2C n F 2n+1 (n represents an integer of 1 to 4), -SO2C n F 2n+1 , methanesulfonate, methanesulfonyl, toluenesulfonate, p-toluenesulfonyl, nitrobenzenesulfonate, p-nitrobenzenesulfonyl, -OSO2Ph, -SO2Ph, and phenoxy, or R2 is phthalimide.
[0098] In one embodiment of the present invention, R3 of the compound represented by formula (I) or (II) is a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent. The “5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group optionally having a substituent” is preferably a 5- to 10-membered monocyclic or polycyclic fully unsaturated or partially saturated heterocyclic group having 1 to 4 hetero atoms selected from nitrogen atoms, oxygen atoms and sulfur atoms; more preferably a pyridazinyl, pyrimidinyl, oxazolyl, oxadiazolyl, pyrazinyl, pyridyl, imidazolyl, furanyl, isoxazolyl, triazolopyridinyl, triazolyl, triazinyl, thiazolyl, thiadiazolyl, imidazopyrazinyl or pyrazolyl; further preferably an isoxazolyl, pyrazolyl, oxazolyl, oxadiazolyl, pyrazinyl or pyridazinyl; further preferably a pyrazolyl, oxazolyl, oxadiazolyl, pyrazinyl or pyridazinyl; particularly preferably a pyrazinyl.
[0099] In one embodiment of the present invention, the "substituent" of the "5-10-membered monocyclic or polycyclic unsaturated heterocyclic group optionally having a substituent" represented by R3 is a halogen atom, a cyano group, an oxy group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy-C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a C1-C6 mono- or di-alkylamino group, a C1-C6 alkylsulfonyl group, a C3-C7 cycloalkyl group, or a C6-C10 aromatic hydrocarbon. Preferably, it is a fluorine atom, a chlorine atom, a cyano group, an oxy group, a C1-C6 alkyl group, a monofluoromethyl group, a methoxyethyl group, a methoxy group, a monofluoromethoxy group, a dimethylamino group, a methylsulfonyl group, a cycloalkyl group, or a phenyl group, more preferably a C1-C6 alkyl group, and even more preferably a methyl group. In the present specification, the number of substituents may be one or more.
[0100] In one embodiment of the present invention, R3 is a 5-10-membered monocyclic or polycyclic unsaturated heterocyclic group optionally having a substituent, preferably a 5-10-membered monocyclic or polycyclic fully unsaturated or partially saturated heterocyclic group optionally having a substituent and having 1 to 4 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, more preferably a pyridazinyl, pyrimidinyl, oxazolyl, oxadiazolyl, pyrazinyl, pyridyl, imidazolyl, furanyl, isoxazolyl, triazolopyridinyl, triazolyl, triazinyl, thiazolyl, thiadiazolyl, imidazopyrazinyl or pyrazolyl optionally having a substituent, more preferably a pyrazinyl optionally having a C1-C6 alkyl group, more preferably a pyrazinyl having a methyl group, and more preferably a 5-methylpyrazine-2-yl group.
[0101] In a preferred embodiment of the present invention, the compound represented by formula (I) is N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide. As also shown in Patent Document 1, this compound is a compound having excellent inhibitory activity and is therefore preferred.
[0102] In one embodiment of the present invention, the by-product generated when the compound represented by formula (II) is derived into the compound represented by formula (I) is not particularly limited as long as it is a compound other than the compound represented by formula (I). It is preferably a by-product converted into the compound represented by formula (I) under alkaline conditions, and more preferably a compound represented by formula (I-1).
[0103]
[0104] (wherein, the definition and implementation of R3 are the same as above)
[0105] For example, when R3 is 5-methylpyrazine-2-yl, the compound represented by formula (I-1) is N-(4-(6-ethynyl-4-(5-methylpyrazine-2-carboxamide)-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide (hereinafter also referred to as compound (2)), and has the following structure.
[0106]
[0107] In the present invention, under alkaline conditions, it refers to a state in which the reaction system is adjusted to alkaline by a base. As the base, as long as the reaction proceeds, there is no particular limitation, for example, as an inorganic base, metal hydroxides (sodium hydroxide, calcium hydroxide, etc.), metal hydrides (lithium hydride, sodium hydride, etc.), metal carbonates (sodium carbonate, potassium carbonate, cesium carbonate, calcium carbonate, lithium carbonate, magnesium carbonate, sodium bicarbonate, etc.) can be listed, as organic bases, metal alkoxides (sodium methoxide, potassium tert-butoxide, etc.), metal amides (sodium amide, lithium diisopropylamide, etc.), alkyl metal compounds (n-butyl lithium, trimethyl aluminum, etc.), alkylamines (triethylamine, tetramethylethylenediamine, piperidine, 1,4-diazabicyclo [2.2.2] octane, etc.), heterocyclic amines (diazabicycloundecane, pyridine, imidazole, etc.) and quaternary ammonium fluoride (tetra-n-butylammonium fluoride), etc. are preferably a base that does not contain fluoride ions, more preferably a metal carbonate or a potassium-containing salt that does not contain fluoride ions, and further preferably potassium carbonate. These can be used alone or in combination for the production method of the present invention.
[0108] The amount of the reagent used is not particularly limited as long as the reaction proceeds, and for example, 0.1 to 50 mol, preferably 0.1 to 10 mol, and more preferably 0.1 to 2 mol, can be used per 1 mol of the compound represented by formula (II).
[0109] There are no particular restrictions on the solvent used in the deprotection step as long as the reaction system can be adjusted to alkaline using a base and the compounds used in the reaction can be dissolved. For example, C5-C10 hydrocarbons, C6-C14 aromatic hydrocarbons, C1-C6 alcohols, C3-C10 aliphatic carbonates, C3-C10 ketones, C4-C10 ethers, aprotic organic solvents, or mixed solvents thereof can be cited. In addition, in this specification, the description represented by the C number refers to the number of carbon atoms, which refers to the total number of carbon atoms contained in such a compound.
[0110] The C5-C10 hydrocarbons are hydrocarbons having 5 to 10 carbon atoms, and examples thereof include pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, and cyclodecane.
[0111] The C6-C14 aromatic hydrocarbons are aromatic hydrocarbons having 6 to 14 carbon atoms, and examples thereof include benzene, naphthalene, anthracene, toluene, xylene, cumene, styrene, and phenanthrene.
[0112] The C1-C6 alcohol is an alcohol having 1 to 6 carbon atoms, and examples thereof include methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, n-pentanol, and n-hexanol.
[0113] The C3-C10 aliphatic carbonate is an aliphatic carbonate having 3 to 10 carbon atoms, and examples thereof include propyl formate, methyl acetate, ethyl acetate, propyl acetate, methyl propionate, ethyl propionate, propyl propionate, methyl butyrate, and ethyl butyrate.
[0114] The C3-C10 ketone is a ketone having 3 to 10 carbon atoms, and examples thereof include acetone, ethyl methyl ketone, diethyl ketone, isopropyl methyl ketone, and cyclohexanone.
[0115] The C4-C10 ether is an ether having 4 to 10 carbon atoms, and examples thereof include diethyl ether, tert-butyl methyl ether, tetrahydrofuran, and 1,4-dioxane.
[0116] The aprotic polar organic solvent refers to a solvent having no ionized protons, and examples thereof include N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, chloroform, and dichloromethane.
[0117] Among the above solvents, dichloromethane, methanol, ethanol, and N-methylpyrrolidone are preferred, and dichloromethane and methanol are more preferred. In addition, the amount of the solvent is not particularly limited as long as the reaction proceeds, but is preferably 10 to 100 L, more preferably 15 to 50 L, and even more preferably 20 to 30 L relative to 1 kg of the compound of formula (II).
[0118] The reaction time of the deprotection step is not particularly limited as long as it is a time that can achieve deprotection, and can be appropriately set, for example, 1 to 120 hours, preferably 6 to 48 hours, and more preferably 12 to 24 hours.
[0119] The reaction temperature of the deprotection step is not particularly limited as long as it is a temperature at which deprotection can be achieved, and can be appropriately set. For example, it is 0 to 60°C, preferably 10 to 50°C, and more preferably 20 to 40°C. (It should be noted that in the present invention, room temperature refers to 18 to 25°C.)
[0120] In addition, according to other embodiments of the present invention, a compound represented by formula (II) can be provided. In addition to manufacturing the compound represented by formula (I), the compound represented by formula (II) is also a useful intermediate. In one embodiment of the present invention, R1, R2 and R3 in the compound represented by formula (II) can be appropriately combined with any of the above options.
[0121] <Reaction pathway>
[0122] A manufacturing method according to one embodiment of the present invention comprises:
[0123] (1) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III) to produce a compound represented by formula (V),
[0124]
[0125] (In the above formulae (III) to (V),
[0126] R1 represents a protecting group,
[0127] R2 represents an amino group optionally having a protecting group, a halogen atom or a leaving group,
[0128] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent,
[0129] R4 represents NR5R5' or NHCOR3, R5 and R5' each independently represent a hydrogen atom or a protecting group of an amino group, or NR5R5' represents phthalimide or a nitro group,
[0130] X represents a halogen atom or a leaving group)
[0131] (2) a step of deprotecting the protecting group represented by R1 of formula (V) under alkaline conditions, and
[0132] (3) According to any selection, before the above (1), R4 of the compound represented by formula (III) is changed to NHCOR3, or after the above (1) and before the above (2), R4 of the compound represented by formula (V) is changed to NHCOR3.
[0133] The reaction of (1) above includes a coupling reaction, and the reaction of (3) above includes a condensation reaction. According to a preferred embodiment of the present invention, after (1) above and before (2) above, R4 of the compound represented by formula (V) is NHCOR3.
[0134] In one embodiment of the present invention, a production method further comprising the following steps is provided: R4 of the compound represented by the above formula (III) and / or R4 of the compound represented by the above formula (V) is NR5R5', and at least one of R5 and R5' is an amino protecting group, and the amino protecting group is deprotected. In a preferred embodiment of the present invention, the amino protecting group is deprotected before the above (1), or after the above (1) and before the above (2), preferably after the above (1) and before the above (2).
[0135] Next, the condensation reaction and Sonogashira coupling performed before deprotection in one embodiment of the present invention are described. The "before deprotection in one embodiment of the present invention" mentioned here means before the above-mentioned "deprotection of the protecting group of the terminal acetylene", and can be applied to immediately before the deprotection or earlier. In addition, the order of the "condensation reaction" and "Sonogashira coupling" mentioned here is not limited, and there may be other reaction steps between the "condensation reaction" and "Sonogashira coupling".
[0136] (When R4 is NHCOR3)
[0137] When R4 in the compound of the above formula (III) is NHCOR3, the compound represented by the following formula (III-2) is used as a starting material, and the above steps (1) and (2) are carried out to obtain the compound represented by the formula (I). In this case, the compound represented by the formula (I) can be obtained without carrying out the step (3). In the following reaction formula, "Deprotection" means "deprotection".
[0138]
[0139] (When R4 is NR5R5')
[0140] In one embodiment of the present invention, when R4 is NR5R5', the following formula (III-1) is used as the starting material, and R4 of the compound represented by formula (III) is changed to NHCOR3 before the above (1), or R4 of the compound represented by formula (V) is changed to NHCOR3 after the above (1) and before the above (2), and finally deprotection is carried out under alkaline conditions, thereby, the compound of formula (I) can be produced.
[0141]
[0142] The following is a production process for the compound of formula (I) (Synthesis Scheme 1). In Synthesis Scheme 1, "Condense" means "condensation reaction" and "Deprotection" means "deprotection".
[0143] Synthesis route 1
[0144]
[0145] In one embodiment of the present invention, R5 and R5' each independently represent a hydrogen atom or a protecting group of an amino group, or NR5R5' represents phthalimide or a nitro group.
[0146] When R5 and / or R5' is a protecting group for amino, or when NR5R5' is phthalimide, the derivatization of the compound represented by formula (III-1) in synthetic route 1 to the compound represented by formula (III-2) and the derivatization of the compound represented by formula (V-1) to the compound represented by formula (II) include a step of deprotecting R5 and / or R5'.
[0147] The "protecting group" in R5 and R5' can be the same as the protecting group exemplified for R2, preferably a carbamate protecting group, more preferably Boc.
[0148] In the present invention, R5 and R5' independently represent a hydrogen atom or a protecting group, or NR5R5' represents phthalimide or nitro. Preferably, R5 and R5' independently represent a hydrogen atom or a protecting group. More preferably, at least one of R5 and R5' represents a protecting group. More preferably, at least one of R5 and R5' represents Boc. It is particularly preferred that R5 is a hydrogen atom or Boc and R5' is a hydrogen atom.
[0149] When NR5R5' is a nitro group, the derivatization from the compound represented by formula (III-1) to the compound represented by formula (III-2) in the synthetic route 1 and the derivatization from the compound represented by formula (V-1) to the compound represented by formula (II) include a step of reducing the nitro group to an amino group. Such reduction can be carried out by a generally known method, specifically, the method described in the "condensation reaction" section described later.
[0150] Since this synthesis route avoids the use of the Ohira-Bestmann method, Sonogashira coupling, condensation reaction (Condense), and derivation from formula (II) to formula (I) can be used in any order. From the perspective of avoiding the use of column chromatography, high yield, and lower impurity content than the production method described in Patent Document 1, it is preferred to produce the compound represented by formula (I) in the following order (A) to (C).
[0151] (A) a compound represented by formula (III-1) is linked to a compound represented by formula (VIII) to derive a compound represented by formula (III-2), or a compound represented by formula (III-1) is linked to a compound represented by formula (IV) to derive a compound represented by formula (V-1)
[0152] (B) A compound represented by formula (II) is derived by connecting a compound represented by formula (III-2) with a compound represented by formula (IV), or connecting a compound represented by formula (V-1) with a compound represented by formula (VIII)
[0153] (C) deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions
[0154] For example, when X is a bromine atom, R1 is TES, R2 is an amino group, R3 is a 5-methylpyrazin-2-yl group, and NR5R5' is an amino group protected by Boc (for example, NHBoc, i.e., R5 or R5' is a protecting group in which either one is a hydrogen atom and the other is an amino group), compound (1) can be produced from tert-butyl (4-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2,2,1]heptane-1-yl)carbamate by subjecting it to Sonogashira coupling, deprotection of Boc (de Boc), and condensation reaction (Condense) in any order, followed by deprotection of TES (de TES).
[0155]
[0156] Such a synthesis procedure is shown below (synthesis route 2).
[0157] Synthesis Path 2
[0158]
[0159] Since this synthetic route avoids the use of the Ohira-Bestmann method, Sonogashira coupling, Boc deprotection (de Boc), condensation reaction (Condense), and TES deprotection (de TES) can be used in any order. From the perspectives of avoiding the use of column chromatography, having a high yield, and reducing the impurity content compared to the production method described in Patent Document 1, it is preferred to produce compound (1) in the following order (A) to (D).
[0160] (A) Coupling of tert-butyl (4-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2,2,1]heptane-1-yl)carbamate and triethylsilyl acetylene
[0161] (B) Deprotection of Boc of the compound obtained in (A)
[0162] (C) Condensation of the compound obtained in (B) with 5-methylpyrazine-2-carboxylic acid
[0163] (D) Deprotection of TES of the compound obtained in (C) under alkaline conditions
[0164] More preferably, compound (1) is produced by the following sequence of (A) to (D).
[0165] (A) Coupling of tert-butyl (4-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2,2,1]heptane-1-yl)carbamate and triethylsilyl acetylene using palladium and copper catalysts
[0166] (B) Deprotection of Boc of the compound obtained in (A)
[0167] (C) Condensation of the compound obtained in (B) with 5-methylpyrazine-2-carboxylic acid using a combination of EDC and HOBt
[0168] (D) Deprotection of TES of the compound obtained in (C) under alkaline conditions adjusted with a reagent not containing fluoride ions
[0169] When a compound of formula (I) or a salt thereof is obtained by such operation, the content of the impurity represented by formula (I-1) can be cited as being low. The content of impurities can be calculated as the ratio (%) of the area of the peak area obtained at a specific wavelength in the measurement using HPLC (high speed liquid chromatography) or UPLC (ultra high speed high separation liquid chromatography). In addition, the wavelength can be appropriately set according to the properties of the compound. This is important for maintaining the quality of pharmaceuticals. Considering the standards stipulated by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), the content of impurities represented by formula (I-1) can be cited as being less than 0.2%. Preferably, it is less than 0.15%, more preferably less than 0.1%, and more preferably less than 0.05%.
[0170] In the compound represented by the above formula (I) and its salt produced by the production method in one embodiment of the present invention, the content of the compound represented by formula (I-1) is 0.2% or less, preferably 0.15% or less, more preferably 0.1% or less, and more preferably 0.05% or less. In addition, the compound represented by formula (I-1) may not be produced by the production method in one embodiment of the present invention, that is, the above ratio is below the detection limit.
[0171]
[0172] (Where,
[0173] R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent)
[0174] According to one embodiment of the present invention, a composition comprising a compound represented by formula (I) or a salt thereof, obtained by the above method can be provided. The composition in one embodiment of the present invention comprises a compound represented by formula (I) or a salt thereof, and a compound represented by formula (I-1). In a preferred embodiment, the ratio of the compound represented by formula (I-1) in the composition is 0.2% or less, preferably 0.15% or less, more preferably 0.1% or less, and more preferably 0.05% or less.
[0175] Impurities generated in the production method can be detected by known methods using known devices, for example, HPLC, which can use commonly available commercial devices.
[0176] In the present invention, the compound represented by formula (I-1) or a salt thereof can be used as a standard for quality management by confirming the stability of a preparation or API containing compound (1) or a salt thereof, and the presence or absence of each analog in the measurement of infrared absorption (IR) spectrum, nuclear magnetic resonance (NMR) spectrum, HPLC, thin layer chromatography (TLC) and other chromatographic methods in the production process. The compound represented by formula (I-1) is preferably N-(4-(6-ethynyl-4-(5-methylpyrazine-2-carboxamide)-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide.
[0177] (Condensation reaction)
[0178] The condensation reaction performed in the present invention is a step for condensing the amine of the compound represented by the following formula (III-1) or formula (V-1) with the carboxylic acid represented by the following formula (VIII) to derive the compound represented by the formula (III-2) or the compound represented by the formula (II) having an amide. That is, the condensation reaction is used to construct the amide bond represented by -NHCOR3 of the compound represented by the formula (III-2) or the compound represented by the formula (II).
[0179]
[0180] (X represents a halogen atom or a leaving group, and the definitions and implementation modes of R2, R5 and R5' are the same as those described above.)
[0181]
[0182] (In the above formulae, X represents a halogen atom or a leaving group, and the definitions and implementation methods of R1, R2, R3, R5 and R5' are the same as above.)
[0183] In the specification, X of the compound represented by formula (III-1) or formula (III-2) is a halogen atom or a leaving group. Examples of the "halogen atom" include fluorine atom, chlorine atom, bromine atom and iodine atom, preferably chlorine atom, bromine atom and iodine atom, more preferably bromine atom and iodine atom, and particularly preferably bromine atom.
[0184] As the "leaving group", the above-mentioned leaving groups can be cited. Preferably, it is -OSO2C n F n+2 (n represents an integer of 1 to 4), methanesulfonate, toluenesulfonate, nitrobenzenesulfonate and -OSO2Ph. Alternatively, the leaving group is preferably -OSO2C n F 2n+1 (n represents an integer of 1 to 4), methanesulfonate, toluenesulfonate, nitrobenzenesulfonate and -OSO2Ph.
[0185] In the compound represented by formula (III-1) or formula (V-1) used in the present condensation reaction, when R5 and R5′ are hydrogen atoms, amide can be constructed by condensation with formula (VIII) by the method shown below.
[0186] In the present condensation reaction, the amount of the compound represented by formula (VIII) is, for example, 0.5 to 5.0 mol, preferably 0.7 to 2.5 mol, more preferably 0.8 to 1.5 mol, further preferably 0.9 to 1.3 mol, particularly preferably 0.9 to 1.1 mol, relative to 1 mol of the compound represented by formula (III-1) or formula (V-1).
[0187] In the compound represented by formula (III-1) or formula (V-1) used in the present condensation reaction, when at least one of R5 and R5' represents an amino protecting group, or NR5R5' represents phthalimide, the amino protecting group needs to be deprotected by an appropriate method to derive R5 and R5' into hydrogen atoms.
[0188] As a method for deprotecting the protecting group of R5 or deriving phthalimide to amino, generally known methods can be used according to each protecting group, specifically, methods such as acidic conditions, alkaline conditions, reduction, and nucleophilic reactions can be used. Under acidic conditions, Boc, Alloc, phthalimide, and Cbz can be deprotected, under alkaline conditions, Fmoc can be deprotected, and under reducing conditions, Cbz and Alloc can be deprotected. In nucleophilic reactions, phthalimide and Ns can be deprotected. In the reaction of fluoride ions, SES can be deprotected. In the deprotection of R5 of the present invention, deprotection under acidic conditions is preferred, and deprotection of Boc under acidic conditions is more preferred.
[0189] In the compound represented by formula (III-1) or formula (V-1) used in the present condensation reaction, when NR5R5' represents a nitro group, it is necessary to convert R5 and R5' into hydrogen atoms by an appropriate method.
[0190] The derivatization can be carried out by generally known methods, for example, reduction by contact hydrogenation using a metal such as Pd, Pt, Ni and a hydrogen source, reduction using a metal such as Fe, Sn, Zn and an acid such as ammonium chloride, hydrochloric acid, acetic acid, or reduction using a hydride such as sodium borohydride or lithium aluminum hydride.
[0191] In the present invention, the above condensation reaction can be carried out at any time before or after the construction of the acetylene described below. That is, formula (III-2) and formula (II) can be derived from formula (III-1) and formula (V-1), respectively. The condensation reaction is preferably carried out after the construction of the terminal acetylene.
[0192] The condensing agent used in the condensation reaction is not particularly limited as long as it allows the reaction to proceed. For example, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or its hydrochloride (WSC or EDC), dicyclohexylcarbodiimide (DCC), 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide methyl-p-toluenesulfonate (CMC), diisopropylcarbodiimide (DIC), 1,3-bis(2,2-dimethyl-1,3-dioxolane-4-ylmethyl)carbodiimide (BDDC) and other carbodiimide condensing agents with 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-aza Benzotriazole (HOAt), ethyl (hydroxyimino) cyanoacetate (Oxyma), N-hydroxysuccinimide (HOSu), a combination of activated ester-forming alcohols such as pentafluorophenol, O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyltetramethylhexaurea hexafluorophosphate (HATU), (1-cyano-2-ethoxy-2-oxoethyleneaminooxy)dimethylaminomorpholinium hexafluorophosphate (COMU) and other urea cation condensation agents, 2-chloro-6-methyl-1,3-diphenyl 2-halogenated-N-alkylpyridinium salts (Mukaiyama condensation reagents) such as pyridinium tetrafluoroborate, 1-methyl-2-chloropyridinium iodide, N,N'-carbonyldiimidazole (CDI), 1,1'-carbonylbis(1,2,4-triazole) (CDT) and other imidazole condensation agents, bromotripyrrolidinophosphine hexafluorophosphate, chlorotripyrrolidinophosphine hexafluorophosphate, 1H-benzotriazol-1-yloxytris(dimethylamino)phosphine hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphine hexafluorophosphate (PyBOP), (7- Phosphine condensation agents such as azabenzotriazol-1-yloxy)tripyrrolidinephosphine (PyAOP), 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride (DMTMM), 4,6-dimethoxy-1,3,5-triazine-2-yl)-(octyloxy-2-oxoethyl) dimethylammonium trifluoromethanesulfonate, 2,4,6-tripropyl-1,3,5,2,4,6-trioxotriphosphane-2,4,6-trioxide (T3P), diphenylphosphine azide (DPPA), etc. Preferably, a combination of a carbodiimide condensation agent and an alcohol for activated ester construction is used, and more preferably, a combination of EDC and HOBt. In addition, these condensation agents include agents supported by polymers.
[0193] The solvent used in the condensation reaction is not particularly limited as long as the reaction proceeds. It can be selected from the same solvent as the solvent used in the deprotection step of the silicon-linked protective group. Preferably, dichloromethane, chloroform, ethyl acetate, dimethyl sulfoxide, diethyl ether, tetrahydrofuran, 1,4-dioxane, acetone, N,N-dimethylformamide, N-methylpyrrolidone, toluene, acetonitrile, tetrahydrofuran, more preferably dichloromethane, chloroform, ethyl acetate, dimethyl sulfoxide, N,N-dimethylformamide, and more preferably dichloromethane and chloroform. In addition, the amount of solvent used is not particularly limited as long as the reaction proceeds. It is preferably 5 to 100 L relative to 1 kg of the reactant, more preferably 15 to 50 L, and more preferably 25 to 35 L.
[0194] When the present condensation reaction is carried out after the formation of the terminal acetylene group, the terminal acetylene group may be protected in advance with a silicon-linked protecting group.
[0195] The reaction time of the condensation step is not particularly limited as long as it is a time that allows condensation, and can be appropriately set, for example, 1 to 120 hours, preferably 2 to 48 hours, more preferably 5 to 48 hours, preferably 8 to 36 hours, and more preferably 14 to 24 hours.
[0196] The reaction temperature of the condensation step is not particularly limited as long as it is a temperature at which condensation can be achieved, and can be appropriately set, for example, 0 to 60°C, preferably 10 to 50°C, and more preferably 20 to 40°C.
[0197] In addition to the combination with the condensing agent represented by formula (VIII) used in the condensation reaction, a combination of the compound represented by formula (VIII-1) or the compound represented by formula (VIII-2) and a base can be mentioned.
[0198]
[0199] Wherein, L represents a halogen atom or a leaving group, and (VIII-1) also includes a mixed acid anhydride, and the definition and embodiment are the same as above, preferably a halogen atom, and more preferably a chlorine atom.
[0200] Examples of the base to be combined with the compound represented by formula (VIII-1) or the compound represented by formula (VIII-2) include organic amines such as trimethylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, diazabicycloundecene (DBU), diazabicyclononene (DBN), pyridine, and 4-dimethylaminopyridine (DMAP); and inorganic bases such as alkali metal hydroxides (lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxides (barium hydroxide, calcium hydroxide, calcium acetate, etc.), alkali metal carbonates (sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, etc.), alkaline earth metal carbonates (barium carbonate, calcium carbonate), alkali metal phosphates (sodium phosphate, potassium phosphate, etc.), acetates (magnesium acetate, potassium acetate, calcium acetate, cesium acetate, etc.).
[0201] Next, the construction of the terminal acetylene is described.
[0202] In general, methods for constructing terminal acetylene include the Corey-Fuchs method, the Seyferth-Gilbert method, the Ohira-Bestmann method, and the Sonogashira coupling. The Corey-Fuchs method requires an aldehyde as a precursor of a dihaloolefin, so its versatility is lower than that of the Sonogashira coupling, which requires an aryl halide. In addition, since the Corey-Fuchs method requires the use of a strong base, a substrate that can withstand strong alkaline conditions is required. In addition, the Seyferth-Gilbert method and the Ohira-Bestmann method require the use of explosive 1-diaza-2-oxopropylphosphonate, and therefore, there are concerns about the large-scale synthesis of pharmaceutical raw materials.
[0203] On the other hand, Sonogao coupling is a cross-coupling reaction of acetylene derivatives with aryl halides or alkyne halides, and has the advantage that it can be carried out without using a strong base or explosive dinitrogen compounds. In addition, the acetylene derivative can be a compound shown in formula (IV) in which one of the two hydrogens possessed by acetylene is replaced by a protecting group, and the terminal acetylene shown in general formula (I) etc. can be constructed with deprotection. A specific example of the protecting group is shown in R1.
[0204] In the present invention, Sonogashira coupling can react the compound represented by formula (III) with the compound represented by the following formula (IV) to synthesize the compound represented by formula (V).
[0205]
[0206]
[0207] (In the above formulae, X, R1, and R2 are the same as defined above. R4 represents NHCOR3 or NR5R5', R5 and R5' independently represent a protecting group of hydrogen or amino, or NR5R5' represents phthalimide or nitro)
[0208] When the compound represented by formula (IV) is introduced into the compound represented by formula (III) by Sonogashira coupling, the quantitative ratio of the compound represented by formula (III) and the compound represented by formula (IV), the ligand of the catalyst of the reaction, the type and amount of the solvent, and the order of addition are also important factors for high purification.
[0209] In the Sonogashira coupling, the amount of the compound represented by formula (IV) is, for example, 1.0 to 5.0 mol, preferably 1.25 to 3.75 mol, and more preferably 1.5 to 2.5 mol, per 1 mol of the compound represented by formula (III).
[0210] The catalyst for Sonogashira coupling is not particularly limited as long as it can promote the reaction. For example, a palladium catalyst can be used alone or in combination with an activator as needed.
[0211] There are no particular restrictions on the palladium catalyst, and examples thereof include carbon-supported palladium (Pd-C), alumina-supported palladium, silica gel-immobilized palladium, palladium acetate, dichlorobis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II), tetrakis(triphenylphosphine)palladium(0), dichloro(1,1-bis(diphenylphosphino)ferrocene)palladium(II), dichlorobis(triphenylphosphine)palladium(II), and the like. The ligand of the catalyst is not particularly limited, and may include tri(o-tolyl)phosphine, tri(tert-butyl)phosphine, triphenylphosphine, dichlorobis(triphenylphosphine), 2-di-tert-butylphosphine-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl, [4-(N,N-dimethylamino)phenyl]di-tert-butylphosphine, di-tert-butyl(4-dimethylaminophenyl)phosphine, tricyclohexylphosphine, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthine (Xantphos), bis(2-(diphenylphosphine)phenyl)ether, etc. The ligand of the catalyst may be a ligand coordinated to the palladium catalyst in advance, or the palladium catalyst and the ligand of the catalyst may be added to a solvent separately and coordinated in the reaction solvent.
[0212] As described above, the palladium catalyst is preferably dichlorobis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II). In addition, its ligand is preferably di-tert-butyl(4-dimethylaminophenyl)phosphine or tricyclohexylphosphine.
[0213] As the activator, a copper catalyst, a silver catalyst, a quaternary ammonium, an aqueous amine solution, etc. can be used. As the copper catalyst, salts having monovalent copper ions can be listed, specifically, copper (I) halides (copper (I) fluoride, copper (I) chloride, copper (I) bromide, copper (I) iodide, copper (I) trifluoromethanesulfonate, etc.) can be listed. As the silver catalyst, salts having monovalent silver ions can be listed, specifically, silver (I) oxide can be listed. As the quaternary ammonium, quaternary ammonium hydroxides (tetra-n-butylammonium hydroxide: TBAOH; tetraethylammonium hydroxide: TEAOH; n-hexadecyltrimethylammonium hydroxide; choline hydroxide, etc.) can be listed. As the aqueous amine solution, aqueous solutions of ammonia, primary amines, secondary amines, tertiary amines, etc. can be listed. As the activator, a copper catalyst is preferred, a salt having monovalent copper ions is more preferred, copper (I) bromide, copper (I) iodide, or copper (I) trifluoromethanesulfonate is more preferred, and copper (I) iodide is particularly preferred.
[0214] The base for the Sonogashira coupling is not particularly limited as long as it is a base that can achieve the introduction of alkyne, and examples thereof include organic bases such as trimethylamine, diethylamine, diisopropylamine (DIPEA), triethylamine (TEA), N-methylmorpholine, diazabicyclononene (DBN), pyridine, 4-dimethylaminopyridine (DMAP), pyridine, morpholine, quinoline, piperidine, diazabicycloundecene (DBU), or inorganic bases such as alkali metal hydroxides (lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxides (barium hydroxide, calcium hydroxide, calcium acetate, etc.), alkali metal carbonates (sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, etc.), alkaline earth metal carbonates (barium carbonate, calcium carbonate), alkali metal phosphates (sodium phosphate, potassium phosphate, etc.), acetates (magnesium acetate, potassium acetate, calcium acetate, cesium acetate, etc.). Preferably, it is an organic base, and more preferably, it is diisopropylethylamine.
[0215] The solvent for the Sonogashira coupling is not particularly limited as long as it is a solvent capable of carrying out the reaction, and examples thereof include N,N-diisopropylethylamine, N-methyl-2-pyrrolidone, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, ethyl acetate, dichloromethane, chloroform, 1,4-dioxane, and toluene. N-methyl-2-pyrrolidone, N,N-dimethylformamide, and N,N-dimethylacetamide are preferred.
[0216] The reaction time of the Sonogashira coupling is not particularly limited as long as it is a time that allows the introduction of the alkyne, and can be appropriately set, for example, 0.5 to 8 hours, preferably 0.5 to 5 hours, and more preferably 1 to 3 hours.
[0217] The reaction temperature of the Sonogashira coupling is not particularly limited as long as it is a temperature at which the introduction of the alkyne can be achieved, and can be appropriately set, for example, 25 to 120°C, preferably 50 to 110°C, and more preferably 80 to 100°C.
[0218] The deprotection of the amino protecting group can be carried out by a known method according to the protecting group. It is deprotection under acidic conditions, deprotection under reducing conditions, deprotection under alkaline conditions, deprotection under palladium catalyst, etc. For example, if it is Boc, by deprotecting under acidic conditions, any acid can be used to set the acidic conditions as long as the deprotection can be carried out. Preferred are trifluoroacetic acid, hydrochloric acid, and sulfuric acid. In addition, the amount of acid used to set the acidic conditions is not particularly limited as long as the reaction can be carried out. For example, relative to 1 mole of the compound represented by formula (I), formula (III), formula (V) or formula (VI), it is preferably 1 to 100 moles, more preferably 2 to 50 moles, and further preferably 3 to 10 moles.
[0219] The solvent used in the deprotection reaction of the amino protecting group is not particularly limited as long as it can carry out the reaction. It can be selected from the same solvent as the solvent used in the deprotection step of the silicon-linked protecting group. It is preferably methanol, ethanol, 2-propanol, acetonitrile, tetrahydrofuran, more preferably methanol, ethanol, 2-propanol, and even more preferably methanol. In addition, the amount of solvent used is not particularly limited as long as it can carry out the reaction. It is preferably 1 to 100 L relative to 1 kg of the reactant, more preferably 5 to 50 L, and even more preferably 10 to 30 L.
[0220] By appropriately adjusting the order, reagent amounts, and solvent amounts of the above-mentioned deprotection of the silicon-linked protecting group under basic conditions, Sonogashira coupling, conversion to R3, and deprotection of the amino protecting group, the target compound can be produced with high purity even without purification by column chromatography.
[0221] The compound (1) produced by the above-mentioned synthesis route may be amorphous or crystalline. When it is crystalline, it may be a single crystal or a mixed crystal of multiple crystals. When crystallized, the compound (1) can be synthesized and used directly without being taken out as a crystal, or it can be temporarily taken out as a crystal (coarse crystal) and used. In addition, a single crystal as the target can be formed by a known purification method. In addition, in this specification, the crystal may be any one of a hydrate or an anhydrous substance.
[0222] A labeled form of compound (1) or a salt thereof, that is, compound (1), a salt of compound (1), or a compound obtained by replacing one or more atoms thereof with a radioactive isotope or a non-radioactive isotope, is also included in one embodiment of the present invention.
[0223] In this specification, chemical purity refers to the purity measured by HPLC. When the chemical purity of compound (1) is expressed, it means the purity of compound (1) measured by HPLC. In this case, the wavelength of the detector used in the purity measurement can be appropriately set. Specifically, the chemical purity of the crystal of compound (1) is preferably 95% or more, more preferably 98% or more, and particularly preferably 99% or more.
[0224] (Avoid the use of explosive reagents)
[0225] In Patent Document 1, acetylene is constructed by the Ohira-Bestmann method to produce compound (1), but the Ohira-Bestmann method is not used in the production method of the present invention.
[0226] As a method for constructing a terminal acetylene without using the Ohira-Bestmann method, a generally known method can be used.
[0227] As one embodiment thereof, it can be mentioned that: a compound represented by formula (VI) is reacted with a compound represented by formula (VII) to obtain a compound represented by formula (IX); and a compound represented by formula (III-1) is obtained from the compound represented by formula (IX). The method for obtaining the compound represented by formula (III-1) from the compound represented by formula (IX) can be, for example, the method described in Patent Document 1.
[0228]
[0229] (wherein L represents a halogen atom or a leaving group)
[0230]
[0231] (In formula (VI) and formula (IX),
[0232] R4 represents NR5R5',
[0233] R5 and R5' each independently represent a hydrogen atom or a protecting group of an amino group, or NR5R5' represents phthalimide or a nitro group,
[0234] L represents a halogen atom or a leaving group)
[0235] (Crystal purification and other operations)
[0236] The precipitated crystals can be separated and purified from a solution or a mixed solution containing the crystals by a known separation and purification method such as filtration, washing with water or an organic solvent, and pressure drying.
[0237] (Activity and Uses)
[0238] The compound or its salt or crystal obtained by the manufacturing method of one embodiment of the present invention has excellent EGFR inhibitory activity. Among them, it has excellent inhibitory activity against EGFR (Del19 / C797S), EGFR (L858R / C797S), EGFR (Del19 / T790M / C797S), EGFR (L858R / T790M / C797S), and is useful as an anti-tumor agent. In addition, the compound or its salt or crystal obtained by the manufacturing method of one embodiment of the present invention has excellent selectivity for mutant EGFR, and has the advantage of having few side effects on wild-type EGFR and other kinases.
[0239] In the present specification, "wild-type EGFR" refers to, for example, the amino acid sequence of GenBank Accession No.: NP_005219.2.
[0240] In the present specification, "Exon 19" refers to the region from 729 to 823 in the amino acid sequence of wild-type EGFR (eg, GenBank Accession No.: NP_005219.2).
[0241] In the present specification, "Del19" means a mutation in which one or more amino acids are deleted in the Exon 19 region of the wild-type EGFR. It also includes a mutation in which one or more arbitrary amino acids are inserted in addition to the deletion in the region. Exon 19 deletion mutations include a mutation in which five amino acids from glutamic acid at position 746 to alanine at position 750 in the Exon 19 region are deleted (DelE746-A750 (or also referred to as d746-750)), a mutation in which seven amino acids from leucine at position 747 to proline at position 753 in the Exon 19 region are deleted and then serine is inserted (Del L747-P753insS), a mutation in which five amino acids from leucine at position 747 to threonine at position 751 in the Exon 19 region are deleted (Del L747-T751), a mutation in which four amino acids from leucine at position 747 to alanine at position 750 in the Exon 19 region are deleted and then proline is inserted (Del L747-A750insP), etc. Preferably, a mutation in which five amino acids from glutamic acid at position 746 to alanine at position 750 in the Exon 19 region are deleted (Del E746-A750).
[0242] The compound or salt thereof obtained by the production method of one embodiment of the present invention can be used for postoperative adjuvant chemotherapy performed after surgical removal of a tumor to prevent recurrence, or can be used for preoperative adjuvant chemotherapy performed in advance for surgical removal of a tumor.
[0243] The tumors that are the subject of the present invention are not particularly limited, and examples thereof include head and neck cancer, digestive system cancer (esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder-choledochal cancer, etc.), pancreatic cancer, colorectal cancer (colorectal cancer, colon cancer, rectal cancer, anal cancer, etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, mesothelioma (pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, testicular mesothelioma, etc.), breast cancer, reproductive system cancer (ovarian cancer, vulvar cancer, uterine cancer (cervical cancer, uterine body cancer, endometrial cancer, etc.), urinary system cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumors, urothelial cancer, renal pelvis cancer, urethral cancer, etc.), hematopoietic system tumors (leukemia, malignant lymphoma, multiple myeloma, etc.), bone-soft tissue tumors, rhabdomyosarcoma, skin cancer, brain tumors, malignant schwannoma, neuroendocrine tumors, thyroid cancer, etc. Preferably, head and neck cancer, breast cancer, colorectal cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, kidney cancer, bladder cancer, skin cancer, brain tumor, particularly preferably lung cancer. In addition, here, cancer not only includes primary lesions, but also includes cancers that are transferred to other organs (liver, etc.). In addition, the compound or its salt or its crystal obtained by the manufacture method of one embodiment of the present invention has excellent inhibitory activity for mutant EGFR. As an example of such mutant EGFR, drug-resistant mutant EGFR and highly sensitive mutant EGFR can be listed. Therefore, the compound of the present invention or its salt is also useful as an antitumor agent for the above-mentioned malignant tumor with mutant EGFR.
[0244] In this specification, the term "effective amount" of a compound refers to the amount of the compound of the present invention that causes a biological or medical response in a subject, such as a reduction or inhibition of enzyme or protein activity, or improves symptoms, alleviates a condition, slows or delays the progression of a disease, etc. (therapeutically effective amount).
[0245] In this specification, the term "subject" includes mammals and non-mammals. In one embodiment, the subject is a human, and may be a person diagnosed as needing treatment for the symptoms, conditions or diseases disclosed in this specification.
[0246] When the compound (1) produced by the above-mentioned production method, the crystal or co-crystal of its salt is used as a medicine, the crystal may be crushed or not, and various administration forms may be adopted according to the therapeutic purpose, and it can be used in a dosage form commonly used as a medicine. As such a form, for example, it can be an oral agent such as a tablet, a capsule, a granule, a fine granule, a powder, a dry syrup; any dosage form of a non-oral agent such as a suppository, an inhalant, a nasal drop, an ointment, a patch, an injection, etc. The pharmaceutical composition suitable for these administration forms can be manufactured by a pharmaceutically acceptable carrier by a conventional preparation method known to those skilled in the art.
[0247] As pharmaceutically acceptable carriers, various organic or inorganic carrier substances commonly used as raw materials for preparations can be used, and they can be used as excipients, binders, disintegrants, lubricants, coating agents in solid preparations, solvents, cosolvents, suspending agents, isotonic agents, buffers, analgesics, etc. in liquid preparations. In addition, preparation additives such as preservatives, antioxidants, colorants, sweeteners, stabilizers, etc. can also be used as needed.
[0248] In the case of preparing a solid preparation for oral administration, an excipient is added to the crystals of compound (1) (i.e., crystals of the free form of compound (1) or crystals of compound (1) and an acid (crystals of a salt or co-crystals)), and a binder, disintegrant, lubricant, colorant, flavoring agent and flavor enhancer are added as needed, and then tablets, coated tablets, granules, powders, capsules, etc. can be manufactured by conventional methods.
[0249] In the case of preparing an injection, a pH adjuster-buffer, a stabilizer, an isotonic agent, a local anesthetic, etc. can be added to the crystals of compound (1) (i.e., crystals of the free form of compound (1) or crystals of compound (1) and an acid (crystals of a salt or a co-crystal)) to produce a subcutaneous, intramuscular or intravenous injection by a conventional method.
[0250] The amount of the crystals of compound (1) to be incorporated into each dosage unit form (i.e., crystals of the free form of compound (1) or crystals of compound (1) and an acid (crystals of a salt or co-crystals)) is not fixed depending on the symptoms of the patient to whom it is applied, the dosage form, etc., but is generally, in terms of the free form of compound (1), it is preferably about 0.05 to 1000 mg for oral preparations, about 0.1 to 500 mg for injections, and about 1 to 1000 mg for suppositories or external preparations.
[0251] The daily dosage of the crystals of compound (1) produced by the above-mentioned production method of the drug having various dosage forms (i.e., crystals of the free form of compound (1) or crystals of compound (1) and an acid (crystals of a salt or co-crystals)) varies depending on the patient's symptoms, body weight, age, sex, etc. and cannot be generalized. Generally, for an adult (weight 50 kg), the daily dosage is about 0.05 to 5000 mg, preferably 0.1 to 1000 mg, calculated as the free form of compound (1).
[0252] (Example Embodiment)
[0253] Although exemplary embodiments of the present invention are described below, the present invention is not limited to the following embodiments.
[0254] The manufacturing method of one embodiment of the present invention is designed to manufacture a compound represented by formula (I) or a salt thereof by deprotecting the protecting group represented by R1 of the compound represented by formula (II). It is preferably a method for manufacturing compound (I) or a salt thereof by deprotecting the protecting group represented by R1 of formula (II) under alkaline conditions. It is more preferred that the method be carried out under alkaline conditions adjusted using a reagent that does not contain fluoride ions, and more preferably the method wherein R1 is triethylsilyl.
[0255] The production method of the present invention in another embodiment is a method for producing a compound represented by formula (I), comprising the steps (A) to (B) in the order shown below.
[0256] (A) A step of reacting a compound represented by formula (IV) with a compound represented by formula (III-2) to produce a compound represented by formula (II)
[0257] (B) Step of deriving the compound represented by formula (II) into the compound represented by formula (I)
[0258] The production method of the present invention in another embodiment is a method for producing a compound represented by formula (I) or a salt thereof, which comprises the following (A) to (C).
[0259] (A) a step of deriving a compound represented by formula (III-2) by connecting a compound represented by formula (III-1) with a compound represented by formula (VIII), or producing a compound represented by formula (V-1) by connecting a compound represented by formula (III-1) with a compound represented by formula (IV);
[0260] (B) a step of deriving a compound represented by formula (II) by connecting a compound represented by formula (III-2) with a compound represented by formula (IV), or by connecting a compound represented by formula (V-1) with a compound represented by formula (VIII); and
[0261] (C) a step of forming a compound represented by formula (I) or a salt thereof by deprotecting the protecting group represented by R1 of formula (II) under basic conditions.
[0262] Preferred is a method for producing a compound represented by formula (I) or a salt thereof, which comprises the following (A) to (C).
[0263] (A) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) to produce a compound represented by formula (V-1);
[0264] (B) a step of deriving the compound represented by formula (V-1) into the compound represented by formula (II); and
[0265] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions.
[0266] More preferably, the method for producing the compound represented by formula (I) or a salt thereof, wherein R1 is a silicon-linked protecting group, R2 is an amino group, R3 is a pyrazinyl group optionally having a methyl group, R4 is NR5R5', R5 is a protecting group capable of being deprotected under acidic conditions, R5' is a hydrogen atom, X is a halogen atom, and L is a halogen atom, comprising the following (A) to (C), excluding a purification step using column chromatography, and the content of the compound represented by formula (I-1) is less than 0.2%.
[0267] (A) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) to produce a compound represented by formula (V-1);
[0268] (B) deprotecting the protecting group of the compound represented by formula (V-1) that can be deprotected under acidic conditions, condensing it with the compound represented by formula (VIII) to derive the compound represented by formula (II); and
[0269] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions.
[0270] Among them, the compound represented by formula (III-1) is derived from a compound represented by formula (IX) obtained by reacting a compound represented by formula (VI) with a compound represented by formula (VII).
[0271] More preferably, the method for producing compound (1) or a salt thereof is, wherein R1 is a silicon-linked protecting group, R2 is an amino group, R3 is a 5-methylpyrazine-2-yl group, R4 is NR5R5', R5 is a protecting group that can be deprotected under acidic conditions, R5' is a hydrogen atom, X is a halogen atom, and L is a halogen atom, comprising the following (A) to (C), excluding a purification step by column chromatography, and the content of compound (2) is 0.2% or less.
[0272] (A) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) to produce a compound represented by formula (V-1);
[0273] (B) a step of deprotecting the protective group of the compound represented by formula (V-1) that can be deprotected under acidic conditions, and deriving the compound represented by formula (II) by condensing it with 5-methylpyrazine-2-carboxylic acid; and
[0274] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions.
[0275] Among them, the compound represented by formula (III-1) is derived from a compound represented by formula (IX) obtained by reacting a compound represented by formula (VI) with a compound represented by formula (VII).
[0276] A further preferred method is a method for producing compound (1) or a salt thereof, wherein R1 is TES, R2 is an amino group, R3 is a 5-methylpyrazine-2-yl group, R4 is NR5R5', R5 is Boc, R5' is a hydrogen atom, X is a bromine atom, and L is a chlorine atom, comprising the following (A) to (C), excluding a purification step using column chromatography, and the content of compound (2) is 0.2% or less.
[0277] (A) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) using a palladium catalyst and a copper catalyst to produce a compound represented by formula (V-1);
[0278] (B) a step of deprotecting the Boc group of the compound represented by formula (V-1) and deriving the compound represented by formula (II) by condensing the compound with 5-methylpyrazine-2-carboxylic acid; and
[0279] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions adjusted using a reagent not containing fluoride ions.
[0280] Among them, the compound represented by formula (III-1) is derived from a compound represented by formula (IX) obtained by reacting a compound represented by formula (VI) with a compound represented by formula (VII).
[0281] Particularly preferred is a method for producing compound (1) or a salt thereof, wherein R1 is TES, R2 is an amino group, R3 is a 5-methylpyrazine-2-yl group, R4 is NR5R5', R5 is Boc, R5' is a hydrogen atom, X is a bromine atom, and L is a chlorine atom, comprising the following (A) to (C), excluding a purification step using column chromatography, and the content of compound (2) is 0.2% or less.
[0282] (A) a step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) using dichlorobis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) and copper(I) iodide to produce a compound represented by formula (V-1);
[0283] (B) a step of deprotecting the Boc of the compound represented by formula (V-1) under acidic conditions, and condensing it with 5-methylpyrazine-2-carboxylic acid using a combination of EDC and HOBt to thereby derive the compound represented by formula (II);
[0284] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions adjusted with potassium carbonate.
[0285] Among them, the compound represented by formula (III-1) is derived from a compound represented by formula (IX) obtained by reacting a compound represented by formula (VI) with a compound represented by formula (VII).
[0286] The manufacturing method of the present invention in another embodiment is a method for manufacturing a composition comprising a compound represented by formula (I) or a salt thereof and a compound represented by formula (I-1). In this method, the ratio of the compound represented by formula (I-1) is 0.2% or less, and a purification step using column chromatography is not included, and the steps are represented in the order of (A) to (C) below.
[0287] (A) A step of reacting a compound represented by formula (IV) with a compound represented by formula (III-1) to produce a compound represented by formula (V-1)
[0288] (B) Step of deriving the compound represented by formula (V-1) into the compound represented by formula (II)
[0289] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions
[0290] The manufacturing method of the present invention in another embodiment is a method for manufacturing a composition comprising a compound represented by formula (I) or a salt thereof and a compound represented by formula (I-1). In this method, the ratio of the compound represented by formula (I-1) is 0.2% or less, and a purification step using column chromatography is not included, and the steps are represented in the order of (A) to (C) below.
[0291] (A) Step of deriving a compound represented by formula (III-1) into a compound represented by formula (III-2)
[0292] (B) Step of deriving the compound represented by formula (III-2) into the compound represented by formula (II)
[0293] (C) A step of deriving the compound represented by formula (II) into the compound represented by formula (I) under alkaline conditions Example
[0294] Hereinafter, the present invention will be described in more detail by way of examples, but the present invention is not limited by these examples. The present invention is fully described by way of examples, but it is understood that various changes and / or modifications can be made by those skilled in the art. Therefore, such changes and / or modifications are all included in the present invention as long as they do not depart from the scope of the present invention.
[0295] In the following examples of compounds, % means weight percentage unless otherwise specified.
[0296] The operation of the apparatus including data processing is according to the methods and steps indicated by the apparatus.
[0297] It should be noted that the numerical values obtained from various spectra may vary to some extent depending on the measurement conditions, etc. Therefore, these numerical values should not be strictly interpreted.
[0298] Apparatus: UPLC manufactured by Waters (% indicates volume percentage)
[0299] Column: ACQUITY UPLC BEH C18 Column, 1.7μm, 2.1mm×50mm (Waters)
[0300] Column temperature: 40°C
[0301] Measurement wavelength: 254nm
[0302] Flow rate: 0.5mL / min
[0303] Mobile phase A: 0.1% formic acid in water
[0304] Mobile phase B: 0.1% formic acid-acetonitrile
[0305] Injection volume: 1 μL
[0306] Gradient: 0→0.1 min: mobile phase B 5%, 0.1→2.1 min: mobile phase B 5→95%, 2.1→3.5 min: mobile phase B 95→98%, 3.5→5 min: mobile phase B 98→95%.
[0307] The operation of the apparatus including data processing is according to the methods and steps indicated by the apparatus.
[0308] Example 1 N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3- Preparation of bicyclo[2.2.1]heptane-1-yl]-5-methylpyrazine-2-carboxamide (compound (1)) make
[0309] (Process 1) Tert-butyl(4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)acetylene Synthesis of 7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)carbamate
[0310] N-methylpyrrolidone (1500 mL) was added to tert-butyl (4-(4-amino-6-bromo-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)carbamate (65.9 g) synthesized by the method described in Patent Document 1, and the mixture was dissolved by stirring at 90° C. for 30 minutes under a nitrogen atmosphere. After cooling to 35° C., diisopropylethylamine (46.5 g), triethylsilylacetylene (33.7 g), copper (I) iodide (4.57 g), dichlorobis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium (II) (8.50 g), and N-methylpyrrolidone (80 mL) were added, and the mixture was stirred at 90° C. for 2 hours under a nitrogen atmosphere. After cooling to 40° C., a 10% sodium dihydrogen phosphate aqueous solution and ethyl acetate were added. The organic layer was washed with dilute ammonia water and water, activated carbon (33.0 g) and SH silica gel (65.9 g) were added, and stirred at 40°C for 1 hour and at room temperature for 2 hours. After the insoluble matter was separated by diatomaceous earth filtration, the solvent was distilled off under reduced pressure, acetonitrile was added to the obtained residue, and stirred at room temperature for 15 hours. The precipitated solid was filtered, washed with acetonitrile, and dried under reduced pressure to obtain the title compound (37.4 g, yield 51%).
[0311] (Process 2) 7-(4-aminobicyclo[2.2.1]heptane-1-yl)-5-(quinolin-3-yl)-6-((tri Synthesis of (ethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
[0312] A 5-10% methanol solution of hydrochloric acid (520 mL) was added to tert-butyl (4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)carbamate (65.0 g) synthesized as described above, and the mixture was stirred at 50° C. for 3 hours under a nitrogen atmosphere. A 2 mol / L aqueous sodium hydroxide solution was added dropwise under ice cooling to adjust the pH to around 12. The precipitated solid was filtered, washed with 50% methanol, and dried under reduced pressure to obtain the title compound (50.3 g, yield 93%).
[0313] (Process 3) N-(4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)acetylene 7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2- Synthesis of carboxamide
[0314] 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (21.9 g) was added to a mixture of 7-(4-aminobicyclo[2.2.1]heptane-1-yl)-5-(quinolin-3-yl)-6-((triethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (48.3 g), 5-methylpyrazine-2-carboxylic acid (13.4 g), 1-hydroxybenzotriazole monohydrate (16.0 g), diisopropylethylamine (24.6 g) and dichloromethane (1450 mL) under a nitrogen atmosphere, and the mixture was stirred for 17 hours. The reaction mixture was washed with a 10% sodium dihydrogen phosphate aqueous solution, a saturated sodium carbonate aqueous solution, and a saturated sodium chloride solution, and dried over anhydrous sodium sulfate. The desiccant was separated by filtration, and the solvent was distilled off under reduced pressure. Methanol was added to the obtained residue, and the mixture was stirred at room temperature for 2 hours. The precipitated solid was collected by filtration, washed with methanol, and dried under reduced pressure to obtain the title compound (54.8 g, yield 92%).
[0315] (Process 4) N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3- Synthesis of (2-(4-(2-(d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide (Compound 1)
[0316] Potassium carbonate (7.03 g) was added to a mixture of N-(4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide (80.0 g) obtained in step 3, dichloromethane (1000 mL), and methanol (1000 mL) under a nitrogen atmosphere, and the mixture was stirred for 18 hours. The insoluble matter was separated by filtration with celite, and the solvent was distilled off under reduced pressure. Methanol and water were added to the obtained residue, and the mixture was stirred for 1 hour. The precipitated solid was filtered, washed with 50% methanol, and dried under reduced pressure to obtain crystals of the title compound (64.5 g, yield 99%) as a pale yellow solid.
[0317] The obtained compound was 1 H-NMR analysis revealed the same result as that of Example 37 of Patent Document 1.
[0318] In addition, as a result of UPLC analysis, the purity was 99.73%, and the content of N-(4-(6-ethynyl-4-(5-methylpyrazine-2-carboxamide)-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide was below the detection limit (less than 0.05%). Comparative Example 1 Synthesis of Compound (1) by a Method Having Condensation in the Final Step
[0319] According to the description of Example 37 of Patent Document 1, 7-(4-aminobicyclo[2.2.1]heptane-1-yl)-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1 equivalent), 5-methylpyrazine-2-carboxylic acid (1 equivalent) and diisopropylethylamine (1.5 equivalents) obtained in Preparation Example 1 of Patent Document 1 were added to 20 mL of dimethyl sulfoxide relative to 1 g of the compound obtained in Preparation Example 1 of Patent Document 1, HATU (1.2 equivalents) was added thereto, and the mixture was stirred at room temperature for 1.5 hours. After confirming the completion of the reaction, water in an amount of about 1 / 3 of the dimethyl sulfoxide was added, and the obtained precipitate was filtered and dried to obtain compound (1) in a yield of 93%. The obtained compound (1) was analyzed by UPLC. As a result, it was found that the purity was 97.3%, and it contained 1.42% of N-(4-(6-ethynyl-4-(5-methylpyrazine-2-carboxamide)-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide.
[0320] It should be noted that all documents and publications recorded in this specification are incorporated into this specification by reference in their entirety, regardless of their purpose. In addition, this specification includes the scope of the patent request, specification and drawings of Japanese patent application No. 2022-071155 (filed on April 22, 2022), which is the basis for claiming priority of this application.
[0321] Several embodiments of the present invention have been described, but these embodiments are presented as examples and are not intended to limit the scope of the invention. These novel embodiments can be implemented in various other ways, and various omissions, substitutions, and changes can be made without departing from the scope of the subject matter of the invention. These embodiments or their variations are included in the scope and subject matter of the invention, and are also included in the invention described in the scope of the patent claim and its equivalent scope.
Claims
1. A method for producing a compound represented by formula (I) or a salt thereof, characterized in that: include: The step of deprotecting the protecting group represented by R1 of formula (II) under alkaline conditions to form a compound represented by formula (I) or a salt thereof, In the formula (I) and formula (II), R1 represents a protecting group, R2 represents an amino group optionally having a protecting group, a halogen atom or a leaving group, R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
2. The manufacturing method according to claim 1, characterized in that: In the formula (I) and formula (II), R1 represents a silicon-bonded protective group, R2 represents an amino group, and R3 represents a pyrazine group optionally having a methyl group.
3. The manufacturing method according to claim 1 or 2, characterized in that: The compound represented by the formula (I) is N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
4. A method for producing a compound represented by formula (I) or a salt thereof, characterized in that: include: (1) a step of deriving a compound represented by formula (III-2) by connecting the compound represented by formula (III-1) with the compound represented by formula (VIII); or a step of producing a compound represented by formula (V-1) by connecting the compound represented by formula (III-1) with the compound represented by formula (IV); (2) a step of deriving a compound represented by formula (II) by connecting the compound represented by formula (III-2) with the compound represented by formula (IV), or by connecting the compound represented by formula (V-1) with the compound represented by formula (VIII); and (3) a step of deprotecting the protecting group represented by R1 of formula (II) under alkaline conditions to form a compound represented by formula (I) or a salt thereof, In the formulae (I), (II), (III-1), (III-2), (IV), (V-1) and (VIII), R1 represents a protecting group, R2 represents an amino group optionally having a protecting group, a halogen atom or a leaving group, R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent, R5 and R5' independently represent a hydrogen atom or an amino protecting group, or NR5R5' represents phthalimide or a nitro group, X represents a halogen atom or a leaving group.
5. The manufacturing method according to claim 4, characterized in that: In the formulae (I), (II), (III-1), (III-2), (IV) and (V-1), R1 represents a silicon-linked protective group, R2 represents an amino group, R3 represents a pyrazinyl group optionally having a methyl group, R4 represents NR5R5', R5 represents a hydrogen atom or Boc, and R5' represents a hydrogen atom.
6. The manufacturing method according to claim 4 or 5, characterized in that: The compound represented by the formula (I) is N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
7. The manufacturing method according to claim 4, characterized in that: Also includes: A step of reacting the compound represented by formula (VI) with the compound represented by formula (VII) to obtain a compound represented by formula (IX); and A step of obtaining a compound represented by formula (III-1) from a compound represented by formula (IX), In formula (VII), L represents a halogen atom or a leaving group, In formula (VI) and formula (IX), R4 represents NR5R5', R5 and R5' independently represent a hydrogen atom or an amino protecting group, or NR5R5' represents phthalimide or a nitro group, L represents a halogen atom or a leaving group.
8. The manufacturing method according to claim 7, characterized in that: In the formulae (VI), (VII) and (IX), R4 represents NR5R5', R5 represents Boc, R5' represents a hydrogen atom, L represents a chlorine atom.
9. The manufacturing method according to claim 4, characterized in that: Purification by column chromatography was not included.
10. The manufacturing method according to claim 9, characterized in that: In the compound represented by the formula (I) and the salt thereof obtained by the method, the content of the compound represented by the formula (I-1) is 0.2% or less, In formula (I-1), R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
11. A composition, characterized in that: It is obtained by the method according to claim 10, and comprises a compound represented by formula (I) or a salt thereof.
12. A compound represented by formula (II) or a salt thereof, In formula (II), R1 represents a protecting group, R2 represents an amino group optionally having a protecting group, a halogen atom or a leaving group, R3 represents a 5- to 10-membered monocyclic or polycyclic unsaturated heterocyclic group which may have a substituent.
13. The compound or salt thereof according to claim 12, characterized in that: In the formula (II), R1 represents a silicon-bonded protecting group, R2 represents an amino group, and R3 represents a pyrazine group optionally having a methyl group.
14. The compound or salt thereof according to claim 12 or 13, characterized in that: The compound represented by the formula (II) is N-(4-(4-amino-5-(quinolin-3-yl)-6-((triethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptane-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
